NPPB and coronary artery disorder: It is recommended that patients with carcinoid syndrome and/or raised 5-hydroxyindoleacetic acid (5-HIAA, a degradation product of 5-HT) levels have 6–12 monthly N-terminal prohormone of brain natriuretic peptide (NT-proBNP) measurements to screen for CHD (5, 6).